Compare abrdn Income Credit Strategies Fund (ACP) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Alnylam Pharmaceuticals, Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while Alnylam Pharmaceuticals, Inc. trades at $324.34 (market cap $42.94B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 65.4× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 17.78% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ACP | ALNY | |
|---|---|---|
Market Cap | $656.21M | $42.94B |
Sector | Financials | Health |
52-Week High | $5.98 | $491.22 |
52-Week Low | $5.01 | $278.09 |
Dividend Yield | 17.78% | — |
Enterprise Value | — | $41.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
Alnylam Pharmaceuticals (ALNY) trades at $321.59, up 2.82% today, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $3.71 billion in 2025, and turned profitable with net income of $313.75 million. Recent news highlights its AI partnerships and expanding drug pipeline as key growth drivers.
The outlook is positive, with a consensus price target of $435.40 implying 35% upside, driven by robust revenue growth and pipeline advancements. Risks include dependence on key drug Amvuttra and high valuation multiples. Analyst sentiment is strongly bullish, with 75% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
